Ropinirole: A dopamine agonist for the treatment of Parkinson's disease

American Journal of Health-System Pharmacy

Volumn 56, Issue 3, 1999, Pages 217-224

  Kuzel, Mary D ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Antiparkinson agents; Clinical studies; Combined therapy; Costs; Dosage; Drug comparisons; Parkinson's disease; Pharmacodynamics; Pharmacokinetics; Ropinirole hydrochloride; Toxicity

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0033082416     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.3.217     Document Type: Review

References (42)

1. Lieberman AN, Gopinathan G, Neophytides A et al. Parkinson's disease handbook. Staten Island, NY: American Parkinson Disease Association; 1996:1.
2. Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993; 329:1021-7.
3. Schapira AHV. Advances in the understanding of the cause of Parkinson's disease. J R Soc Med. 1994; 87:373-5. Editorial.
4. Stern MB. The changing standard of care in Parkinson's disease: current concepts and controversies. Neurology. 1997; 49(suppl 1):S1.
5. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand. 1991; 84(suppl 136):6-15.
6. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology. 1990; 40(suppl 3):32-7.
7. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease and the potential role of dopamine agonists. Neurology. 1997; 49(suppl 1):S26-33.
8. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology. 1998; 50(suppl 3):S6.
9. Ahlskog JE. Treatment of Parkinson's disease: from theory to practice. Postgrad Med. 1994; 95:52,54,57-8,61-4,68-9.
10. Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin. 1992; 10:527-40.
11. Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs. 1996; 5:369-88.
12. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci. 1992; 19:108-12.
13. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989; 321:1364-71.
14. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993; 328:176-83.
15. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997; 49(suppl 1):S58-62.
16. 2 agonist. Pharmacol Biochem Behav. 1991; 38:147-54.
17. 2 receptors of rate cerebral cortex. Gen Pharmacol. 1986; 17:57-62.
18. 2 cortical receptors. Biol Signals. 1994; 3:223-9.
19. Langtry HD, Clissold SP. Pergolide: a review of its pharmacological potential in Parkinson's disease. Drugs. 1990; 39:491-506.
20. McPherson GA. In vitro selectivity of lisuride and other ergot derivatives for alpha-1 and alpha-2 adrenoceptors. Eur J Pharmacol. 1984; 97:151-5.
21. 4 receptors. Eur J Pharmacol. 1995; 290:29-36.
22. Pahwa R, Koller WC. Dopamine agonists in the treatment of Parkinson's disease. Cleve Clin J Med. 1995; 62:212-7.
23. Ruffolo RR, Cohen ML, Messick K et al. Alpha-2-adrenoceptor mediated effects of pergolide. Pharmacology. 1987; 35:148-54.
24. Silbergeld EK, Hruska RE. Effects of ergot drugs on serotonergic function: behaviour and neurochemistry. Eur J Pharmacol. 1979; 58:1-10.
25. 2-receptor agonist. Br J Clin Pharmacol. 1991; 32:483-8.
26. Boothman BR, Spokes EGS. Pharmacokinetic data for ropinirole. Lancet. 1990; 2:814. Letter.
27. Requip package insert. Philadelphia: SmithKline Beecham Pharmaceuticals; 1997.
28. Mirapex package insert. Kalamazoo, MI: Pharmacia & Upjohn; 1997.
29. Parlodel package insert. East Hanover, NJ: Sandoz Pharmaceuticals; 1997.
30. Permax package insert. South San Francisco, CA: Athena Neurosciences; 1997.
31. Hauser H, Zaslowicz T. Parkinson's disease: questions and answers. 2nd ed. Coral Springs, FL: Merit Publishing International; 1997.
32. Thalamas C, Rayet S, Brefel C et al. Effect of food on the pharmacokinetics of ropinirole in patients with Parkinson's disease. Paper presented at Fourth International Congress of Movement Disorders. Vienna, Austria; 1996 Jun 16-21.
33. Kaye C, Taylor AC, Beerahee A et al. Lack of pharmacokinetic interaction between ropinirole and digoxin or L-dopa in Parkinson's disease patients. Paper presented at the American Society of Consultant Pharmacists 27th Annual Meeting. Nashville, TN; 1996 Nov 14-15.
34. Taylor AC, Cyronak M, Citerone DR et al. Lack of a pharmacokinetic interaction between ropinirole and theophylline in parkinsonian patients. Br J Clin Pharmacol. In press.
35. Pearce RKB, Banerji T, Jenner P et al. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug-naive MPTP-treated common marmosets. Br J Pharmacol. 1996; 118:38P.
36. 2-like receptor agonist. Eur J Pharmacol. 1994; 265:17-26.
37. Adler CH et al. Ropinirole for the treatment of early Parkinson's disease. Neurology. 1997; 49:393-9.
38. Rascol O, for the Study Group. A double blind L-dopa controlled study of ropinirole in de novo patients with Parkinson's disease. Paper presented at Fourth International Congress of Movement Disorders. Vienna, Austria; 1996 Jun 16-21.
39. 2 agonist, as an adjunct to L-dopa (DCI) in patients with Parkinson's disease. Paper presented at Fourth International Congress of Movement Disorders. Vienna, Austria; 1996 Jun 16-21.
40. Ropinirole 043 Study Group. A double-blind comparative study of ropinirole vs bromocriptine in the treatment of parkinsonian patients not optimally controlled on L-dopa. Paper presented at Fourth International Congress of Movement Disorders. Vienna, Austria; 1996 Jun 16-21.
41. Prescription pricing guide. Indianapolis, IN: Medi-Span; 1998 Mar.
42. Watts RL. The role of dopamine agonists in early Parkinson's disease. Neurology. 1997; 49(suppl 1):S34-48.